Vaccines and plasma company CSL faces ongoing cost pressures that have hit profits and market value but the underlying performance remains strong, the biomedical leader says.
CEO Paul McKenzie, facing shareholders at his first AGM as CEO of Australia's third-largest company, said CSL had had to navigate a difficult macroeconomic environment.
